OncoMatch/Clinical Trials/NCT06944106
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Is NCT06944106 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies AK112 for pancreatic cancer.
Treatment: AK112 — This trial is a prospective, single-arm, single-center Phase II clinical study aimed at evaluating the efficacy and safety of Ivonescimab combined with the gemcitabine and nab-paclitaxel (AG) regimen as neoadjuvant therapy for borderline resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage BORDERLINE RESECTABLE
Borderline resectable disease
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immunotherapy (anti-pd-1, anti-pd-l1, anti-pd-l2, anti-ctla-4)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.5×10⁹/l, platelets (plt) ≥100×10⁹/l, hemoglobin (hb) ≥90 g/l, white blood cells (wbc) ≥3.0×10⁹/l
Kidney function
serum creatinine (cr) ≤1.5×uln or creatinine clearance ≥60 ml/min (calculated by cockroft-gault formula)
Liver function
alt and ast ≤2.5×uln; total bilirubin ≤1.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06944106 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BORDERLINE RESECTABLE is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages